Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.
Industries BiotechnologyHealth CareTherapeuticsWellnessHeadquarters Regions Greater New York Area, East Coast, Northeastern US Founded Date Sep 2017 Founders Andrew L. Pecora, Peter Diamandis, Robert J. Hariri Operating Status Active Last Funding Type Post-IPO Equity Legal Name Celularity, Inc.
Stock Symbol NASDAQ:CELU Company Type For Profit
Contact Email media@celularity.com Phone Number 908-768-2170
Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting
indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.